Grifols (GRFS) Cash from Financing Activities (2010 - 2020)
Grifols (GRFS) reported Cash from Financing Activities of -$121.5 million for Q1 2020, down 93.07% on a YoY basis from -$1.8 billion in Q2 2019, and up 54.2% quarter-over-quarter from -$265.2 million in Q4 2019.
Grifols (GRFS) Cash from Financing Activities (2010 - 2020) Analysis & Trends
Grifols has reported Cash from Financing Activities for 10 years, with the latest figure at -$121.5 million in Q1 2020.
- For the quarter ending Q1 2020, Cash from Financing Activities fell 93.07% year-over-year to -$121.5 million; the trailing twelve-month figure through Mar 2020 stood at -$356.2 million (down 120.86% YoY), and the FY2025 full-year result was -$615.8 million, up 57.6% from the prior year.
- Cash from Financing Activities for Q1 2020 stood at -$121.5 million, up from -$265.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $1.8 billion in Q4 2017, with the low at -$265.2 million in Q4 2019.
- Historically, Cash from Financing Activities has averaged $236.6 million across 5 years, with a median of -$62.9 million in 2019.
- Annual changes were most pronounced in 2017 — Cash from Financing Activities jumped 1301.8% — and 2019, when it tumbled 503.89%.
- Grifols' Cash from Financing Activities stood at -$146.6 million in 2016, then soared by 1301.8% to $1.8 billion in 2017, then slumped by 94.7% to $93.4 million in 2018, then slumped by 383.88% to -$265.2 million in 2019, then soared by 54.2% to -$121.5 million in 2020.
- The last three Cash from Financing Activities figures came in at -$121.5 million (Q1 2020), -$265.2 million (Q4 2019), and -$62.9 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 366.70 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -121.48 Mn |
| Mar 31, 2020 | -121.48 Mn |
| Dec 31, 2019 | -265.22 Mn |
| Dec 31, 2019 | -265.22 Mn |
| Mar 31, 2019 | -62.92 Mn |
| Mar 31, 2019 | -62.92 Mn |
| Dec 31, 2018 | 93.43 Mn |
| Dec 31, 2018 | 93.43 Mn |
| Jun 30, 2018 | -207.36 Mn |
| Jun 30, 2018 | -207.36 Mn |
| Mar 31, 2018 | 15.58 Mn |
| Mar 31, 2018 | 15.58 Mn |
| Dec 31, 2017 | 1.76 Bn |
| Dec 31, 2017 | 1.76 Bn |
| Jun 30, 2017 | -97.45 Mn |
| Jun 30, 2017 | -97.45 Mn |
| Mar 31, 2017 | 1.67 Bn |
| Mar 31, 2017 | 1.67 Bn |
| Dec 31, 2016 | -146.57 Mn |
| Dec 31, 2016 | -146.57 Mn |